Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Provectus Biopharmaceuticals Inc (OP:PVCT)

0.0970 -0.0030 (-3.00%)
Streaming Delayed Price Updated: 11:48 AM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 49,190
Open 0.0979
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1000
Today's Range 0.0910 - 0.0999
52wk Range 0.0445 - 0.1995
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Noninvasive Eye Infection Treatment Shows Promise
(NewsUSA) - Those who suffer from eye infections that threaten a person’s vision have a new treatment option that is noninvasive and counters the problem of antibiotic resistance, based on recent... 
Via NewsUSA
PVCT Stock Earnings: Provectus Reported Results for Q2 2024
Provectus just reported results for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
-19.4%
-19.4%
1 Month
-5.9%
-5.9%
3 Month
-20.4%
-20.4%
6 Month
-0.9%
-0.9%
1 Year
-49.0%
-49.0%

More News

Read More
PVCT Stock Earnings: Provectus Reported Results for Q1 2024
Via InvestorPlace
PVCT Stock Earnings: Provectus Reported Results for Q4 2023
Via InvestorPlace
Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December
Via Benzinga
Provectus Biopharmaceuticals Announces Decision to Not Undertake Reverse Split of Outstanding and Authorized Equities in 2022; Expects to Seek Same Stockholder Approval Again in 2023
From Provectus Biopharmaceuticals Inc.
Via GlobeNewswire
Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10® and Keytruda® for First-Line Stage III Melanoma at Melanoma Bridge 2022
From Provectus Biopharmaceuticals Inc.
Via GlobeNewswire
Provectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 2022
From Provectus Biopharmaceuticals Inc.
Via GlobeNewswire
Provectus Biopharmaceuticals Announces World Health Organization Selection of “Rose Bengal Sodium” as International Nonproprietary Name for Active Pharmaceutical Ingredient
From Provectus Biopharmaceuticals Inc.
Via GlobeNewswire
Provectus Biopharmaceuticals Expands Research Collaboration with The Rockefeller University to Investigate Clinical-Stage Immuno-Dermatology Agent PH-10 for Skin Inflammation
From Provectus Biopharmaceuticals Inc.
Via GlobeNewswire
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Texas Medical Branch at Galveston to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal for Wound Healing
From Provectus Biopharmaceuticals Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Provectus Biopharmaceuticals Inc publicly traded?
Yes, Provectus Biopharmaceuticals Inc is publicly traded.
What exchange does Provectus Biopharmaceuticals Inc trade on?
Provectus Biopharmaceuticals Inc trades on the OTC Traded
What is the ticker symbol for Provectus Biopharmaceuticals Inc?
The ticker symbol for Provectus Biopharmaceuticals Inc is PVCT on the OTC Traded
What is the current price of Provectus Biopharmaceuticals Inc?
The current price of Provectus Biopharmaceuticals Inc is 0.0970
When was Provectus Biopharmaceuticals Inc last traded?
The last trade of Provectus Biopharmaceuticals Inc was at 04/01/25 11:48 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.